Antidiabetic Potentials of Catechin in Combination with Metformin: An In vitro and Molecular Docking Study
Abstract
Objective: This work aims to evaluate the combined anti-diabetic effects of metformin and catechin in vitro and in silico. Methods: In vitro, anti-diabetic potentials of (α-amylase and α-glucosidase) catechin, metformin, and a combination of catechin and metformin were studied at different concentrations using acarbose as standard. An in silico study determined their binding interactions with α-amylase (PDB ID: 1hvx) and α-glucosidase (PDB ID: 5zcb). The molecular docking study further revealed the binding energy and interacting residues of the docked 3D structure of the catechin, metformin, and acarbose as a standard with the α-amylase and α-glucosidase receptors. Results: The result showed that a 100 μg/ml dosage of metformin and catechin demonstrated higher enzyme inhibition compared to the separate treatments. Compared to metformin and acarbose, the results of this study showed that catechin with 1hvx and 5zcb exhibited the highest binding affinity interaction via hydrogen bonding and pi-interaction. Conclusion: The study's findings showed that when compared to metformin and acarbose, catechin with 1hvx and 5zcb showed the highest binding affinity relationship via hydrogen bonding and pi-interaction. Higher levels of enzyme inhibition were seen when metformin and catechin were administered together than when either medication was taken alone. Based on the aforementioned report, we deduced that metformin and catechin together had more potent antidiabetic actions in vitro.…
Read the paper
Related studies
- Metformin as an adjuvant in breast cancer treatment
- Metformin Lysosomal Targeting: A Novel Aspect to Be Investigated for Metformin Repurposing in Neurodegenerative Diseases?
- Aberrant HSF1 signaling activation underlies metformin amelioration of myocardial infarction in mice
- Metformin induces ZFP36 by mTORC1 inhibition in cervical cancer-derived cell lines
- Protein Interaction Network for Identifying Vascular Response of Metformin (Oral Antidiabetic)
- Preventing Long COVID With Metformin
Go deeper in Evidence Hub
Evidence Hub adds a study data sheet (design, sample size, evidence level, key numbers), an AI summary and a chat grounded in the paper's text.